Nam Atiqur Rahman (Atiqur Rahman, Nam A Rahman)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 12

Top Topics

Small Cell Lung Cancer

Epidermal Growth Factor Receptor

Myasthenia Gravis

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Clinical pharmacology and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Nam Atiqur Rahman, Mirat Shah, Stacy S Shord
Dosage Optimization: A Regulatory Perspective for Developing Oncology Drugs. Clinical pharmacology and therapeutics (2024)
Michael I Barbato, Diana Bradford, Yi Ren, Stephanie L Aungst, Claudia P Miller, Lili Pan, Jeanne F Zirkelbach, Yangbing Li, Youwei Bi, Jianghong Fan, Manuela Grimstein, Sarah E Dorff, Anup K Amatya, Pallavi S Mishra-Kalyani, Barbara Scepura, Peter Schotland, Opeyemi Udoka, Idara Ojofeitimi, John K Leighton, Nam Atiqur Rahman, Richard Pazdur, Harpreet Singh, Paul G Kluetz, Nicole Drezner
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
Michael I Barbato, Diana Bradford, Yi Ren, Stephanie L Aungst, Claudia P Miller, Lili Pan, Jeanne F Zirkelbach, Yangbing Li, Youwei Bi, Jianghong Fan, Manuela Grimstein, Sarah E Dorff, Anup K Amatya, Pallavi S Mishra-Kalyani, Barbara Scepura, Peter Schotland, Opeyemi Udoka, Idara Ojofeitimi, John K Leighton, Nam Atiqur Rahman, Richard Pazdur, Harpreet Singh, Paul G Kluetz, Nicole Drezner
FDA Approval Summary: Repotrectinib for locally advanced or metastatic ROS1-positive non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Nam Atiqur Rahman, Mirat Shah, Stacy S Shord
Dosage Optimization: A Regulatory Perspective for Developing Oncology Drugs. Clinical pharmacology and therapeutics 116 (3) (2024)
Michael J Fusco, Sandra J Casak, Sirisha L Mushti, Joyce Cheng, Brian J Christmas, Matthew D Thompson, Wentao Fu, Hezhen Wang, Miyoung Yoon, Yuching Yang, Jason N Moore, Youwei Bi, Yang Nan, Craig E Long, Doris Auth, Nam Atiqur Rahman, Shenghui Tang, Richard Pazdur, Lola A Fashoyin-Aje, Paul G Kluetz, Steven J Lemery
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Michael J Fusco, Sandra J Casak, Sirisha L Mushti, Joyce Cheng, Brian J Christmas, Matthew D Thompson, Wentao Fu, Hezhen Wang, Miyoung Yoon, Yuching Yang, Jason N Moore, Youwei Bi, Yang Nan, Craig E Long, Doris Auth, Nam Atiqur Rahman, Shenghui Tang, Richard Pazdur, Lola A Fashoyin-Aje, Paul G Kluetz, Steven J Lemery
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (15) (2024)
Michael H Brave, William F Maguire, Chana Weinstock, Hui Zhang, Xin Gao, Fang Li, Jingyu Yu, Wentao Fu, Hong Zhao, William F Pierce, Elaine Chang, Jeannette Dinin, Mallorie H Fiero, Nam Atiqur Rahman, Shenghui Tang, Richard Pazdur, Paul G Kluetz, Laleh Amiri-Kordestani, Daniel L Suzman
FDA Approval Summary: Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Michael J Fusco, Sandra J Casak, Sirisha L Mushti, Joyce Cheng, Brian J Christmas, Matthew D Thompson, Wentao Fu, Hezhen Wang, Miyoung Yoon, Yuching Yang, Jason N Moore, Youwei Bi, Yang Nan, Craig E Long, Doris Auth, Nam Atiqur Rahman, Shenghui Tang, Richard Pazdur, Lola A Fashoyin-Aje, Paul G Kluetz, Steven J Lemery
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (15) (2024)
Michael I Barbato, Diana Bradford, Yi Ren, Stephanie L Aungst, Claudia P Miller, Lili Pan, Jeanne F Zirkelbach, Yangbing Li, Youwei Bi, Jianghong Fan, Manuela Grimstein, Sarah E Dorff, Anup K Amatya, Pallavi S Mishra-Kalyani, Barbara Scepura, Peter Schotland, Opeyemi Udoka, Idara Ojofeitimi, John K Leighton, Nam Atiqur Rahman, Richard Pazdur, Harpreet Singh, Paul G Kluetz, Nicole Drezner
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
Michael J Fusco, Sandra J Casak, Sirisha L Mushti, Joyce Cheng, Brian J Christmas, Matthew D Thompson, Wentao Fu, Hezhen Wang, Miyoung Yoon, Yuching Yang, Jason N Moore, Youwei Bi, Yang Nan, Craig E Long, Doris Auth, Nam Atiqur Rahman, Shenghui Tang, Richard Pazdur, Lola A Fashoyin-Aje, Paul G Kluetz, Steven J Lemery
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (15) (2024)
Michael I Barbato, Diana Bradford, Yi Ren, Stephanie L Aungst, Claudia P Miller, Lili Pan, Jeanne F Zirkelbach, Yangbing Li, Youwei Bi, Jianghong Fan, Manuela Grimstein, Sarah E Dorff, Anup K Amatya, Pallavi S Mishra-Kalyani, Barbara Scepura, Peter Schotland, Opeyemi Udoka, Idara Ojofeitimi, John K Leighton, Nam Atiqur Rahman, Richard Pazdur, Harpreet Singh, Paul G Kluetz, Nicole Drezner
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
Asma Dilawari, Mirat Shah, Gwynn Ison, Haley Gittleman, Mallorie H Fiero, Ankit Shah, Salaheldin S Hamed, Junshan Qiu, Jingyu Yu, Wimolnut Manheng, Tiffany K Ricks, Rajan Pragani, Arulvathani Arudchandran, Paresma Patel, Shadia Zaman, Arpita Roy, Shyam Kalavar, Soma Ghosh, William F Pierce, Nam Atiqur Rahman, Shenghui Tang, Bronwyn D Mixter, Paul G Kluetz, Richard Pazdur, Laleh Amiri-Kordestani
FDA Approval Summary: Mirvetuximab soravtansine-gynx for FRα-positive, Platinum-Resistant Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)